Last 139.10 INR
Change Today 0.00 / 0.00%
Volume 0.0
JBCP On Other Exchanges
Symbol
Exchange
Natl India
As of 7:32 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

j.b. chemicals & pharma ltd (JBCP) Snapshot

Open
139.00
Previous Close
138.20
Day High
141.50
Day Low
137.15
52 Week High
04/15/14 - 144.35
52 Week Low
06/25/13 - 72.30
Market Cap
11.8B
Average Volume 10 Days
443.9K
EPS TTM
9.38
Shares Outstanding
84.7M
EX-Date
08/1/13
P/E TM
14.8x
Dividend
3.00
Dividend Yield
2.15%
Current Stock Chart for J.B. CHEMICALS & PHARMA LTD (JBCP)

Related News

No related news articles were found.

j.b. chemicals & pharma ltd (JBCP) Related Businessweek News

No Related Businessweek News Found

j.b. chemicals & pharma ltd (JBCP) Details

J. B. Chemicals & Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations, herbal remedies, bulk drugs, intermediates, and radio-diagnostics in India and internationally. The company’s product portfolio consists of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, and active pharmaceutical ingredients. It offers prescription drugs in the areas of anthelmintics, anti diarrhoeal, antibiotics and chemotherapeutic agents, ant diabetics, antihistamine systemics, cardiovascular/cardiac care, G.I/prokinetic, G.I/antiulcerant, nasal decongestants, neuro/psychiatry, NSAID's/antirheumatic, nutritional and tonics, radio diagnostics, sex stimulants, tropical preparations, and urology; over the counter products for cough and cold, tropical antibacterial/antiseptic, dental preparations, multivitamins and rejuvenators, and sex stimulants; and herbal preparations for cough and cold, and multivitamins and rejuvenators. The company markets its products under Doktor Mom, Metrogyl, Rantac, Nicardia Retard, OF, Dicloran, Cilacar, and Rantac MPS brand names. It also exports its products to the United States, Europe, Africa, the Commonwealth of Independent States, the Middle East, Southeast Asia, and Latin America. J. B. Chemicals & Pharmaceuticals Ltd. was founded in 1959 and is headquartered in Mumbai, India.

Founded in 1976

j.b. chemicals & pharma ltd (JBCP) Top Compensated Officers

Chairman, Managing Director and Member of Sha...
Total Annual Compensation: 14.3M
President, Director of Operations and Whole-T...
Total Annual Compensation: 5.2M
Director of Technical & Production and Execut...
Total Annual Compensation: 3.2M
Director of Administration, Whole-Time Direct...
Total Annual Compensation: 14.3M
Director of Planning & Development and Whole-...
Total Annual Compensation: 5.7M
Compensation as of Fiscal Year 2013.

j.b. chemicals & pharma ltd (JBCP) Key Developments

J. B. Chemicals & Pharmaceuticals Ltd., Board Meeting, Apr 15, 2014

J. B. Chemicals & Pharmaceuticals Ltd., Board Meeting, Apr 15, 2014. Agenda: To approve a scheme of amalgamation and arrangement between Jyotindra Mody Holdings Private Limited and Ansuya Mody Securities Private Limited and Dinesh Mody Securities Private Limited and Kumud Mody Securities Private Limited and Shirish B. Mody Investments Private Limited and Bharati S. Mody Investments Private Limited and J.B. Chemicals & Pharmaceuticals Limited and their respective shareholders under Sections 391 to 394 of the Companies Act, 1956 read with Sections 100 to 103 of the Companies Act, 1956 and Section 55 of the Companies Act, 2013 and other applicable provisions of the Companies Act, 1956 and the Companies Act, 2013.

J. B. Chemicals & Pharmaceuticals Ltd. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

J. B. Chemicals & Pharmaceuticals Ltd. reported unaudited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported total income from operations of INR 2,395.217 million against INR 2,042.923 million for the same period previous year. Profit from operations before other income and finance costs was INR 369.114 million against INR 193.597 million for the same period of previous year. Profit from ordinary activities before tax was INR 12.753 million against INR 312.375 million for the same period of previous year. Net loss after tax was INR 64.746 million or INR 0.76 per basic and diluted share compared to net profit after tax of INR 218.740 million or INR 2.58 per basic and diluted share for the same period of previous year. For the nine months, the company reported total income from operations of INR 7,279.361 million against INR 6,112.791 million for the same period previous year. Profit from operations before other income and finance costs was INR 1,113.300 million against INR 590.396 million for the same period of previous year. Profit from ordinary activities before tax was INR 690.338 million against INR 849.114 million for the same period of previous year. Net profit after tax was INR 469.936 million or INR 5.55 per basic and diluted share compared to INR 651.862 million or INR 7.69 per diluted share for the same period of previous year.

J. B. Chemicals & Pharmaceuticals Ltd. Appoints Krupa R. Gandhi as an Additional Director

J. B. Chemicals & Pharmaceuticals Ltd. announced that the Board of Directors of the company has appointed Krupa R. Gandhi, partner of Bansi S. Mehta & Co., Chartered Accountants, as an additional director of the company. She is an independent director on the Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JBCP:IN 139.10 INR 0.00

JBCP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JBCP.
View Industry Companies
 

Industry Analysis

JBCP

Industry Average

Valuation JBCP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact J.B. CHEMICALS & PHARMA LTD, please visit www.jbcpl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.